Project Grant R01DA060632
Award Date
4/15/25
Completion Date
2/28/29
Dollars Obligated
$634K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,916,991.00 to support a Phase 1B clinical trial of the novel therapeutic agent MT-110 for the reduction of methamphetamine use disorder (MUD). The trial will recruit up to 44 patients to test 5 dose levels of MT-110 and determine central nervous system drug concentrations. The primary endpoints are focused on assessing the safety and...
The National Institute on Drug Abuse (NIDA) awarded a $223,715 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington to explore the neurobehavioral effects of concurrent opioid and methamphetamine use disorders. The key objectives are to: 1) Define the behavioral profile of dual opioid-methamphetamine use disorders in a rodent model, comparing polysubstance and mono-substance addiction patterns, and 2) Map neural activation patterns within...
This $810,668 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate an immunotherapeutic compound called DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The primary objective is to assess DRHQ's effects on drug-seeking behavior, cognitive function, and inflammation in preclinical animal models of stimulant use disorder. The research...
This Project Grant award of $188,525 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support the development and validation of a Patient-Reported Outcomes for Methamphetamine Treatment (PROMT) survey. The goal is to create a validated instrument to assess patient-reported outcomes for new medications to treat methamphetamine use disorder, as no such validated tool currently exists. The study will involve developing a...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a research project focused on developing a new treatment for opioid use disorder (OUD). The award of $1,837,542 will support a two-phase clinical trial investigating the safety, efficacy, and mechanisms of action of combining the medication ketamine with the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) for patients with...
This Project Grant award, totaling $3,469,296, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award will fund research at the University of California, Los Angeles (UCLA) to investigate the effects of methamphetamine use on inflammasome activation, chronic inflammation, and immune dysfunction in individuals with HIV infection. The key objectives are to: 1) determine the impacts of methamphetamine on inflammasome...
The National Institute on Drug Abuse (NIDA) awarded a 5-year, $1,499,050 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Medical College of Wisconsin, Inc. The grant, titled "Investigations into 5-HT2A Signaling Mechanisms of Psychedelic Drugs for the Treatment of Stimulant Use Disorder," will fund research to examine the role of the 5-HT2A receptor signaling pathway in psychedelic drugs' therapeutic potential for treating stimulant use disorders,...
This federal Project Grant award of $1,481,760 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the "Methamphetamine Activation of Inflammasome and Altered Immunity in HIV (MAIA) Study" at Emory University. The primary objective is to investigate how methamphetamine use leads to inflammasome activation and immune dysfunction in people living with HIV on antiretroviral therapy, even when viral loads are...
The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $177,170 Project Grant to the University of Massachusetts Medical School (UMass Medical) to assess strategies for implementing Medications for Opioid Use Disorder (MOUD) treatment in Massachusetts jails. The 3-year project, beginning in June 2024, aims to qualitatively evaluate organizational factors related to MOUD implementation, investigate staff perspectives on MOUD, and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to evaluate the efficacy of combining the drug guanfacine and the behavioral intervention mindfulness meditation as an adjunct to buprenorphine maintenance treatment for individuals with opioid use disorder (OUD). The $1,264,863 award, spanning September 2024 to August 2026, will be used to conduct a two-stage study. In the first...